Table 3.
Odds ratios and 95% confidence intervals for CRP plasma level and prostate cancer from unconditional logistic regression
| CRP Plasma Quartile (Range, mg/L) | P-value† | ||||
|---|---|---|---|---|---|
| 1 | 2 | 3 | 4 | ||
| 0.02–0.36 | 0.37–0.75 | 0.76–1.51 | 1.52–42.0 | ||
| Controls, N | 128 | 128 | 130 | 129 | |
|
| |||||
| All prostate cancer* | |||||
| Cases, N (%) | 128 (21.3) | 156 (25.9) | 139 (23.1) | 179 (29.7) | |
| OR (95% CI) | 1.00 (Ref) | 1.21 (0.86, 1.70) | 1.06 (0.74, 1.51) | 1.37 (0.96, 1.95) | 0.11 |
|
| |||||
| Tumor stage*: | |||||
| Localized (T1/T2) | |||||
| Cases, N (%) | 84 (23.9) | 91 (25.9) | 76 (21.7) | 100 (28.5) | |
| OR (95% CI) | 1.00 (Ref) | 1.07 (0.72, 1.57) | 0.88 (0.58, 1.32) | 1.14 (0.76, 1.72) | 0.49 |
| Extra-prostatic (T3/T4/N1/M1) | |||||
| Cases, N (%) | 28 (20.9) | 33 (24.6) | 32 (23.9) | 41 (30.6) | |
| OR (95% CI) | 1.00 (Ref) | 1.16 (0.65, 2.08) | 1.11 (0.61, 2.02) | 1.45 (0.80, 2.62) | 0.27 |
|
| |||||
| Tumor grade*: | |||||
| Gleason 2–6/Well differentiated | |||||
| Cases, N (%) | 78 (22.2) | 100 (28.5) | 74 (21.1) | 99 (28.2) | |
| OR (95% CI) | 1.00 (Ref) | 1.26 (0.86, 1.86) | 0.91 (0.60, 1.38) | 1.21 (0.80, 1.83) | 0.57 |
| Gleason 7 | |||||
| Cases, N (%) | 27 (21.6) | 27 (21.6) | 33 (26.4) | 38 (30.4) | |
| OR (95% CI) | 1.00 (Ref) | 1.03 (0.56, 1.86) | 1.31 (0.72, 2.37) | 1.59 (0.87, 2.91) | 0.09 |
| Gleason 8–10/Poorly differentiated | |||||
| Cases, N (%) | 11 (13.9) | 22 (27.9) | 19 (24.0) | 27 (34.2) | |
| OR (95% CI) | 1.00 (Ref) | 2.01 (0.93, 4.36) | 1.65 (0.74, 3.70) | 2.37 (1.07, 5.23) | 0.10 |
|
| |||||
| BMI‡: | |||||
| <25 kg/m2 | |||||
| Cases, N (%) | 93 (26.3) | 89 (25.2) | 78 (22.1) | 93 (26.4) | |
| Controls, N (%) | 99 (32.1) | 83 (27.0) | 67 (21.7) | 59 (19.2) | |
| OR (95% CI) | 1.00 (Ref) | 1.14 (0.75, 1.73) | 1.26 (0.80, 1.98) | 1.73 (1.09, 2.74) | 0.02 |
| ≥ 25 kg/m2 | |||||
| Cases, N (%) | 35 (14.1) | 67 (26.9) | 61 (24.5) | 86 (34.5) | |
| Controls, N (%) | 29 (14.0) | 45 (21.8) | 63 (30.4) | 70 (33.8) | |
| OR (95% CI) | 1.00 (Ref) | 1.20 (0.64, 2.25) | 0.72 (0.38, 1.33) | 0.90 (0.49, 1.65) | 0.56 |
*
Analyses of total prostate cancer and prostate cancer subgroups adjusted for BMI (continuous), aspirin treatment (yes vs. no) and matching factors (age, smoking status and follow-up time) unless otherwise indicated
†
P-value from score test using a 4-level ordinal variable based on medians within each quartile of CRP
‡
Stratified analysis adjusted for BMI (continuous), aspirin treatment (yes vs. no) and matching factors (age, smoking status and follow-up time); pinteraction = 0.08 (dichotomous BMI and ordinal CRP level)